Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

soft tissue tumours

- PMLiVE

Ogsiveo recommended by NICE to treat rare soft tissue tumours

Desmoid tumours are rare soft tissue tumours that can grow aggressively into nearby tissues

- PMLiVE

LEO Pharma acquires rights for dersimelagon from Tanabe Pharma

The company will pay $435m in up front and near-term milestone payments

- PMLiVE

US FDA accepts supplemental Biologics License Application for Merck’s Enflonsia

The treatment is to protect children under two years of age from respiratory syncytial virus

- PMLiVE

LEO Pharma to acquire Replay gene therapy platform

The acquisition will advance innovation for patients with rare skin diseases

- PMLiVE

Shionogi starts phase 2 clinical trial for Pompe Disease

The rare disease affects around one in every 22,000 people worldwide

- PMLiVE

PharmaQuest returns: EPA perspectives, through a rare disease lens

By Lottie Sequerra and Emily Morton-West

Amiculum

- PMLiVE

Merck agrees on $2.2bn deal with Quotient Therapeutics to develop IBD treatment

Quotient’s somatic genomics platform technology will be used to develop the treatment

- PMLiVE

Incyte Biosciences UK announces NICE approval for Opzelura for vitiligo

This is the first approved treatment option in the UK for patients with non-segmental vitiligo

- PMLiVE

UCB’s Kygevvi receives positive CHMP opinion for thymidine kinase 2 deficiency

TK2d is an extremely rare disease characterised by severe and progressive muscle weakness

- PMLiVE

Sanofi announces positive results for venglustat in type 3 Gaucher disease

There are currently no approved treatments for the neurological symptoms of this disease

- PMLiVE

Moderna and Merck announce data from melanoma combination therapy study

Skin cancer is one of the most common cancers in the US, with melanoma accounting for the majority of skin cancer deaths

- PMLiVE

Merck announces agreement with US government to reduce prices of prescription medication

The pharma company will invest more than $70bn in the US to boost production and innovation

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links